November_New Drugs｜GAI New Drug Development Wave Continues to Ramp Up

GAI's new drug development tools are revolutionizing the process of new drug discovery and development, specializing in specific genes, diseases, drug screening and clinical applications, and covering the entire value chain of new drug development, from disease mechanism, searching for new targets, drug design, formulation design, clinical trial design, clinical execution management, testing and registration, quality control and manufacturing applications, GAI accelerates the speed, efficiency, risk reduction, error reduction and cost reduction of new drug discovery and development. GAI can accelerate the speed and efficiency of the new drug discovery and development process by reducing risks, errors and costs, by establishing correlations between different datasets, by analyzing precisely the key biomolecules and pathways of disease progression, and by accelerating the discovery of new drugs by discovering never-before-discovered therapeutic insights out of the box, or by designing candidate molecules using GAI, by filtering and designing new molecules from a multimodal database and by predicting their metabolism and physicochemical properties. GAI can be used to design candidate molecules by screening and designing new molecules from multimodal databases and predicting their pharmacokinetic and physicochemical properties to avoid potential side effects, thus accelerating the prediction of more safe and effective candidate molecules to enter the clinic; or analyzing patient e-case data and evaluating the risk, screening more suitable trial populations and accelerating the speed of recruitment for clinical trials to streamline the clinical trials under the premise of ensuring that clinical trial participants are sufficiently representative of the target therapeutic population; or in the regulatory review stage, GAI can also assist pharmaceutical experts to automate the process of regulatory review and to identify new drugs. GAI can also assist pharmaceutical experts in automating the preparation of 60% clinical study reports, reducing the 35-week document preparation timeframe to 5-7 weeks, which helps to minimize the time required to produce study reports in addition to rigorously reviewing regulatory paperwork.

the (whole) worldAINew drug development continues40%Ko Shing Cheung!

According to markets&markets report, the global AI drug discovery market will reach US$900 million in 2023, and is estimated to grow 5.4 times to US$4.9 billion in 2028, with an annual compound growth rate of 40%, and the global AI new drug development will continue to grow at a high rate of 40% for the second consecutive year. In 2023, almost every large pharmaceutical company will start cooperation with various AI/ML pharmaceutical companies, and the content of cooperation will be more abundant and close. Companies using GAI technology to design small molecules and biologic drug candidates have been the focus of biopharmaceutical deals in recent years, and fundraising has continued to heat up, from NVIDIA's series of investments in drug discovery companies such as Terray Therapeutics, Inceptive (mRNA), Superluminal Medicines, and RecursionAI, to Open AI's participation in drug discovery companies. From NVIDIA's series of investments in drug discovery companies such as Terray Therapeutics, Inceptive (mRNA), Superluminal Medicines, and RecursionAI, to Open AI's participation in Formation Bio, and the success of Xaira Therapeutics, a start-up GAI pharmaceutical company, which raised $1 billion, the GAI-enabled drug development market continues to be optimistic.

The reason why the capital market is optimistic about the development of GAI Pharmaceuticals comes from the fact that international pharmaceutical companies generally recognize GAI's advantages in innovation, efficiency and cost reduction. From the demand side, under the situation of new drug R&D dilemmas and the rising cost of new drug development year by year, as well as the U.S. inflationary IRA act to inhibit the price of new drugs, the international pharmaceutical companies need to be more careful in their investment in new drugs, and GAI's algorithmic language model has become an important solution to address the pain points and reduce R&D costs. GAI Pharmaceuticals' specific algorithmic language modeling, coupled with the rich drug R&D experience and data of international pharmaceutical companies, has become an important solution for international pharmaceutical companies to address their pain points and reduce R&D costs. At present, GAI-assisted drug discovery and molecular optimization are the most mature. According to Drug Discovery Today, the success rate of drug molecules generated by GAI is as high as 80-90%, which is better than the average value of 50% in the industry's history, and pharmaceutical giants, such as Roche, Novartis, Sanofi, Lilly, and Gilead, are all heavily investing in the expansion of GAI-assisted new drug discovery. Roche, Sanofi, Eli Lilly, Gilead and other pharmaceutical giants have also invested heavily in expanding GAI-assisted new drug costs, and Modena has deployed 750 GPTs in collaboration with OPEN AI to strengthen the efficiency of clinical, vaccine development, and internal management, and the application of GAI is rapidly covering the entire new drug development journey.

Taiwan AccelerationGAISieving for a different path and a chance to turn the corner

This year's Nobel Prize in Physics and Chemistry Award Ceremony, AI undoubtedly became the biggest winner, with the rapid development of global GAI technology, GAI is becoming a drug discovery, drug design, drug screening, drug development and clinical design and other areas of the key tools, whether it is the international pharmaceutical companies or Taiwan factories are very much attached to GAI technology in the development of new drugs in the application of the efficiency and cost advantages in the strategy, the international pharmaceutical companies mostly with various types of specialized areas of GAI pharmaceutical companies to solve the difficulties faced by the various aspects of new drug development, but also through the acquisition or independent development of GAI internal and external. In terms of strategy, international pharmaceutical companies mostly cooperate with various GAI pharmaceutical companies specializing in various fields to solve the difficulties faced in various aspects of new drug development, and also conduct internal and external double validation through acquisition or self-development of GAI to determine the potential of drug development candidates. In the face of limited competitive resources, Taiwan companies are using GAI technology to increase the success rate of drug screening and the opportunities for new uses of old drugs. For example, Advent Biomedical, which specializes in protein degradation drugs, has adopted Pfizer's BioNeMo generative AI platform to screen out two brand new compounds in three years, and will be applying for human clinical trial authorization for the new drugs at the end of the year; and Spectrum has used its self-constructed AI model to design the new drug YA-101, which was awarded the U.S. FDA's orphan drug award for the treatment of multiple degenerative diseases. YA-101, a new drug for multiple systemic degenerative disorders designed with its own AI model, has been approved by the U.S. FDA as an orphan drug and is entering Phase 2 clinical trials.

-For more information, please contact us at